The turnaround story continues, with a strong balance sheet, Improving profitability & cashflow across their business units. There is also considerable upside from the growth in Nextstellis sales. Would have been great to see a divi.
- Forums
- ASX - By Stock
- MYX
- Ann: 2024 Full Year Results Media Release
MYX
mayne pharma group limited
Add to My Watchlist
1.34%
!
$5.29

Ann: 2024 Full Year Results Media Release, page-18
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.29 |
Change
0.070(1.34%) |
Mkt cap ! $430.1M |
Open | High | Low | Value | Volume |
$5.29 | $5.33 | $5.15 | $275.1K | 52.16K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 517 | $5.28 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.30 | 266 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 141 | 5.300 |
5 | 378 | 5.290 |
4 | 1812 | 5.280 |
5 | 30741 | 5.270 |
3 | 1722 | 5.260 |
Price($) | Vol. | No. |
---|---|---|
5.310 | 1035 | 10 |
5.320 | 451 | 2 |
5.330 | 452 | 3 |
5.340 | 8476 | 7 |
5.350 | 20472 | 4 |
Last trade - 13.41pm 18/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online